Jorge Santos da Silva, MoonLake Immunotherapeutics CEO (via website)

Moon­Lake's CEO on its loom­ing mid-year piv­otal read­out in skin dis­ease

MI­A­MI — Moon­Lake Im­munother­a­peu­tics is ex­pect­ed to have one of the biotech in­dus­try’s biggest stock-mov­ing clin­i­cal read­outs around the mid­dle of this year for a pair …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.